NCT04960722 is a NA clinical trial of OIF/β-TCP in Tibia Fracture, sponsored by BioGend Therapeutics Co.Ltd.

Who is sponsoring NCT04960722?

NCT04960722 is sponsored by BioGend Therapeutics Co.Ltd.

What drugs are being tested in NCT04960722?

Interventions in NCT04960722: OIF/β-TCP.

What condition does NCT04960722 study?

NCT04960722 studies Tibia Fracture.

Is NCT04960722 still recruiting?

NCT04960722 is currently completed. Last updated 24 September 2025.

Last reviewed 2025-09-24 · How we verify

NCT04960722

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

OIF/β-TCP in Patients With Open Tibial Fractures in Need of Bone Grafting

Completed NA Last updated 24 September 2025

What this trial tests

NA trial testing OIF/β-TCP in Tibia Fracture in 35 participants. Completed in 25 February 2025.

Timeline

11 January 2022

Primary endpoint
24 September 2024

25 February 2025

Quick facts

Lead sponsor	BioGend Therapeutics Co.Ltd
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	35
Start date	11 January 2022
Primary completion	24 September 2024
Estimated completion	25 February 2025
Sites	1 location across Taiwan

Drugs / interventions tested

OIF/β-TCP

Conditions studied

Tibia Fracture — all drugs for Tibia Fracture →

Sponsor

BioGend Therapeutics Co.Ltd

Who can join

21 and older, any sex, with Tibia Fracture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, randomized, evaluator-blinded, controlled study for subjects with open tibial fractures classified as Gustilo type II, IIIA or IIIB (see Appendix 1) who will receive bone graft implantation for the potential of delayed union or non-union within 3 months of fracture. Subjects will be followed for safety and clinical performance for the main study period of 30 weeks and an extension follow-up period up to 52 weeks after bone graft implantation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Tibia Fracture

Currently open trials in the same condition.

NCT05859451 — Effect of Tobacco Heating System (THS) on Closed Lower Limb Fracture Healing · NA · recruiting
NCT05151926 — Limb Injuries and Post Injury Rehabilitation Trials - Tibial Shaft Fracture · NA · recruiting
NCT05668182 — A Case Series: TRUMATCH Graft Cage for Segmental Long Bone Defects · recruiting

Other BioGend Therapeutics Co.Ltd trials

Trials by the same sponsor.

NCT05924763 — The Clinical Outcome of BiCRI in the Treatment of Chondral and Osteochondral Lesions · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04960722 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BioGend Therapeutics Co.Ltd
Last refreshed: 24 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04960722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing